Biomarker testing identifies high-risk early-stage NSCLC patients for adjuvant chemotherapy, reducing recurrence risk by 78%. The AIM-HIGH study shows a 96% disease-free survival rate at 24 months ...

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced xM for treatment response ...

A groundbreaking study reveals that ultrasensitive ctDNA assays significantly enhance prognosis for large B-cell lymphoma, outperforming traditional PET assessments.

– Blue Shield of California has over 3 million covered members in CA – SAN FRANCISCO, March 6, 2023 /PRNewswire/ -- Invitae (NVTA), a leading medical genetics company, today announced that its ...

The Signatera assay showed positive correlations between ctDNA presence and cancer recurrence, suggesting its potential for ...